{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T10:48:19Z","timestamp":1790765299877,"version":"4.1.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["CRSII3 160742\/1"],"award-info":[{"award-number":["CRSII3 160742\/1"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["IG2010-10104"],"award-info":[{"award-number":["IG2010-10104"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["IG2013-14201"],"award-info":[{"award-number":["IG2013-14201"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["IG2017-20258"],"award-info":[{"award-number":["IG2017-20258"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007076","name":"Fondazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007076","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007388","name":"Compagnia di San Paolo","doi-asserted-by":"publisher","award":["2008.1054"],"award-info":[{"award-number":["2008.1054"]}],"id":[{"id":"10.13039\/100007388","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.ymthe.2018.05.020","type":"journal-article","created":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T10:42:42Z","timestamp":1533120162000},"page":"2008-2018","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Therapeutic Silencing of miR-214 Inhibits Tumor Progression in Multiple Mouse Models"],"prefix":"10.1016","volume":"26","author":[{"given":"Daniela","family":"Dettori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Orso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Penna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D\u00e9sir\u00e9e","family":"Baruffaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Brundu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Maione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilia","family":"Turco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Giraudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Taverna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2018.05.020_bib1","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.cell.2006.11.001","article-title":"Cancer metastasis: building a framework","volume":"127","author":"Gupta","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2018.05.020_bib2","first-page":"74","article-title":"Global cancer statistics, 2002","volume":"55","author":"Parkin","year":"2005","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ymthe.2018.05.020_bib3","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.addr.2014.05.009","article-title":"In\u00a0vivo delivery of miRNAs for cancer therapy: challenges and strategies","volume":"81","author":"Chen","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ymthe.2018.05.020_bib4","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1038\/emboj.2011.102","article-title":"microRNA-214 contributes to melanoma tumour progression through suppression of TFAP2C","volume":"30","author":"Penna","year":"2011","journal-title":"EMBO J."},{"key":"10.1016\/j.ymthe.2018.05.020_bib5","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1101\/gad.1820109","article-title":"MicroRNA dynamics in the stages of tumorigenesis correlate with hallmark capabilities of cancer","volume":"23","author":"Olson","year":"2009","journal-title":"Genes Dev."},{"key":"10.1016\/j.ymthe.2018.05.020_bib6","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1756-8722-3-46","article-title":"Dysregulation of miR-15a and miR-214 in human pancreatic cancer","volume":"3","author":"Zhang","year":"2010","journal-title":"J.\u00a0Hematol. Oncol."},{"key":"10.1016\/j.ymthe.2018.05.020_bib7","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.1158\/0008-5472.CAN-12-3686","article-title":"miR-214 coordinates melanoma progression by upregulating ALCAM through TFAP2 and miR-148b downmodulation","volume":"73","author":"Penna","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2018.05.020_bib8","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.semcancer.2008.01.001","article-title":"Changes in miRNA expression in solid tumors: an miRNA profiling in melanomas","volume":"18","author":"Moln\u00e1r","year":"2008","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.ymthe.2018.05.020_bib9","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1158\/1078-0432.CCR-09-2721","article-title":"Melanoma microRNA signature predicts post-recurrence survival","volume":"16","author":"Segura","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2018.05.020_bib10","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1097\/CMR.0b013e3282feeac6","article-title":"Micro-RNAs associated with metastasis in uveal melanoma identified by multiplexed microarray profiling","volume":"18","author":"Worley","year":"2008","journal-title":"Melanoma Res."},{"key":"10.1016\/j.ymthe.2018.05.020_bib11","doi-asserted-by":"crossref","first-page":"9136","DOI":"10.1073\/pnas.0508889103","article-title":"microRNAs exhibit high frequency genomic alterations in human cancer","volume":"103","author":"Zhang","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2018.05.020_bib12","doi-asserted-by":"crossref","first-page":"11612","DOI":"10.1158\/0008-5472.CAN-07-5019","article-title":"Altered microRNA expression confined to specific epithelial cell subpopulations in breast cancer","volume":"67","author":"Sempere","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2018.05.020_bib13","first-page":"336","article-title":"Differential expression of microRNAs in tissues and plasma co-exists as a biomarker for pancreatic cancer","volume":"7","author":"Ali","year":"2015","journal-title":"J.\u00a0Cancer Sci. Ther."},{"key":"10.1016\/j.ymthe.2018.05.020_bib14","doi-asserted-by":"crossref","first-page":"R214","DOI":"10.1186\/gb-2007-8-10-r214","article-title":"MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype","volume":"8","author":"Blenkiron","year":"2007","journal-title":"Genome Biol."},{"key":"10.1016\/j.ymthe.2018.05.020_bib15","doi-asserted-by":"crossref","first-page":"5151","DOI":"10.1158\/0008-5472.CAN-15-1322","article-title":"miR-214 and miR-148b targeting inhibits dissemination of melanoma and breast cancer","volume":"76","author":"Orso","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2018.05.020_bib16","doi-asserted-by":"crossref","first-page":"3030","DOI":"10.1007\/s11095-011-0548-9","article-title":"MicroRNA replacement therapy for cancer","volume":"28","author":"Henry","year":"2011","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ymthe.2018.05.020_bib17","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nrd.2016.246","article-title":"MicroRNA therapeutics: towards a new era for the management of cancer and other diseases","volume":"16","author":"Rupaimoole","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2018.05.020_bib18","series-title":"Antisense Drug Technology: Principles, Strategies and Applications","first-page":"3","article-title":"Mechanisms of antisense drug action, an introduction","author":"Crooke","year":"2007"},{"key":"10.1016\/j.ymthe.2018.05.020_bib19","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0140-6736(16)31715-9","article-title":"Safety, tolerability, and antiviral effect of RG-101 in patients with chronic hepatitis C: a phase 1B, double-blind, randomised controlled trial","volume":"389","author":"van der Ree","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2018.05.020_bib20","doi-asserted-by":"crossref","first-page":"121ra18","DOI":"10.1126\/scitranslmed.3003205","article-title":"MicroRNA-21 promotes fibrosis of the kidney by silencing metabolic pathways","volume":"4","author":"Chau","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2018.05.020_bib21","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1172\/JCI75852","article-title":"Anti-microRNA-21 oligonucleotides prevent Alport nephropathy progression by stimulating metabolic pathways","volume":"125","author":"Gomez","year":"2015","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2018.05.020_bib22","doi-asserted-by":"crossref","first-page":"e100951","DOI":"10.1371\/journal.pone.0100951","article-title":"Anti-miRs competitively inhibit microRNAs in Argonaute complexes","volume":"9","author":"Hogan","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ymthe.2018.05.020_bib23","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1038\/mt.2014.5","article-title":"Multifunctional aptamer-miRNA conjugates for targeted cancer therapy","volume":"22","author":"Esposito","year":"2014","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2018.05.020_bib24","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.addr.2015.01.008","article-title":"Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides","volume":"87","author":"Geary","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ymthe.2018.05.020_bib25","doi-asserted-by":"crossref","first-page":"3738","DOI":"10.1002\/dvdy.21787","article-title":"Dnm3os, a non-coding RNA, is required for normal growth and skeletal development in mice","volume":"237","author":"Watanabe","year":"2008","journal-title":"Dev. Dyn."},{"key":"10.1016\/j.ymthe.2018.05.020_bib26","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/nbt.1618","article-title":"Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model","volume":"28","author":"Ma","year":"2010","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2018.05.020_bib27","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1016\/j.ymthe.2016.11.016","article-title":"RNA nanoparticle-based targeted therapy for glioblastoma through inhibition of oncogenic miR-21","volume":"25","author":"Lee","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2018.05.020_bib28","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1158\/1541-7786.MCR-07-0344","article-title":"Gene expression changes in an animal melanoma model correlate with aggressiveness of human melanoma metastases","volume":"6","author":"Xu","year":"2008","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.ymthe.2018.05.020_bib29","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1038\/nature03799","article-title":"Genes that mediate breast cancer metastasis to lung","volume":"436","author":"Minn","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2018.05.020_bib30","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1158\/1541-7786.MCR-15-0425-T","article-title":"miR-146a exerts differential effects on melanoma growth and metastatization","volume":"14","author":"Raimo","year":"2016","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.ymthe.2018.05.020_bib31","first-page":"3356","article-title":"Semaphorin 3A is an endogenous angiogenesis inhibitor that blocks tumor growth and normalizes tumor vasculature in transgenic mouse models","volume":"119","author":"Maione","year":"2009","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2018.05.020_bib32","doi-asserted-by":"crossref","first-page":"9054","DOI":"10.1038\/srep09054","article-title":"The cholesterol biosynthesis enzyme oxidosqualene cyclase is a new target to impair tumour angiogenesis and metastasis dissemination","volume":"5","author":"Maione","year":"2015","journal-title":"Sci. Rep."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152500161830248X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152500161830248X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:52:42Z","timestamp":1761501162000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152500161830248X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":32,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["S152500161830248X"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2018.05.020","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic Silencing of miR-214 Inhibits Tumor Progression in Multiple Mouse Models","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2018.05.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}